Aclasta against osteoporosis and fractures

Novartis publishes the results of the first study performed on Aclasta , an osteoporosis drug in patients with hip fractures. It has been seen that administering Aclasta once a year prevents new fractures by 35% and improves life in a certain sense. In fact, it would seem that in the group of patients analyzed the intake of Aclasta has prolonged life by decreasing the risk of death by 28%, just think that the fracture of the femur represents the most frequent cause of mortality and disability of about a quarter of the population above the 50 years to which is added the merciless statistical calculation which shows a 5-fold increase in the probability of experiencing new fractures for patients who have already fractured their femur. The risk of subsequent spine fractures is reduced by 46% and of new non-vertebral fractures (such as hip, wrist, arm, leg, rib) by 27%. Although the study was not intended to detect major differences in hip fractures, it did show a trend towards a 30% reduction in new hip fractures. Aclasta is still awaiting formal approval by the EMEA. and has recently been approved in the United States, under the name of Reclast, for the treatment of postmenopausal osteoporosis.